1122597-31-2

Upstream product

• 2687-43-6 O-benzylhydoxylamine hydrochloride 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 660-88-8 5-aminopentanoic acid 
• 622-33-3 N-benzyloxyamine 
• 27219-07-4 5-(N-tert-butyloxycarbonyl)aminopentanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1122748-10-0 C₁₂H₁₈N₂O₂ 
• 1349028-98-3 C₃₃H₃₉N₃O₇ 
• 1349029-01-1 C₃₂H₃₇N₃O₇ 
• 1349029-02-2 C₄₉H₅₃F₃N₈O₉ 
• 1349029-04-4 C₃₄H₄₁F₃N₈O₇ 

Relevant academic research and scientific papers

MDM2-HDAC double-target inhibitor, medicinal composition and preparation and application of MDM2-HDAC double-target inhibitor

The invention provides a MDM2-HDAC double-target inhibitor, a medicinal composition and preparation and application of the MDM2-HDAC double-target inhibitor. The MDM2-HDAC double-target inhibitor hasa structure as shown in formula I. The inhibitor with th

Preparation of bifunctional isocyanate hydroxamate linkers: Synthesis of carbamate and urea tethered polyhydroxamic acid chelators

Two novel bifunctional N-methylhydroxamate-isocyanate linkers 20 and 21 were prepared in good yield and high purity from the corresponding amine salts using a biphasic reaction with phosgene. The facile ring opening reaction of N-Boc lactams using the anion of O-benzylhydroxylamine gave the protected amino hydroxamates 6a and 6c in good yields. The selective methylation of the hydroxamate nitrogen in the presence of the N-Boc group in these intermediates could be readily accomplished. The utility of the linkers was clearly demonstrated by the synthesis of the carbamate-tethered trishydroxamic acid 27 and the urea-tethered 29.

COMPOUND, SYNTHESIS, COMPOSITION AND USES THEREOF

The instant application provides the disclosure for a compound of formula I, synthesis of compound of formula I and its pharmaceutical acceptable salts, as well as its polymorphs, solvates, and hydrates thereof. The pharmaceutically acceptable salt may be

HDAC INHIBITORS

The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.